nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—Graves' disease	0.496	1	CbGaD
Thalidomide—CYP2E1—Methimazole—Graves' disease	0.129	0.367	CbGbCtD
Thalidomide—CYP2C19—Methimazole—Graves' disease	0.0809	0.23	CbGbCtD
Thalidomide—CYP1A2—Methimazole—Graves' disease	0.0746	0.212	CbGbCtD
Thalidomide—CYP2C9—Methimazole—Graves' disease	0.0672	0.191	CbGbCtD
Thalidomide—Erythema nodosum—Propylthiouracil—Graves' disease	0.00439	0.074	CcSEcCtD
Thalidomide—Pomalidomide—TNF—Graves' disease	0.00333	1	CrCbGaD
Thalidomide—Neuritis—Methimazole—Graves' disease	0.00299	0.0504	CcSEcCtD
Thalidomide—Interstitial lung disease—Propylthiouracil—Graves' disease	0.00268	0.0452	CcSEcCtD
Thalidomide—Neuritis—Propylthiouracil—Graves' disease	0.00254	0.0429	CcSEcCtD
Thalidomide—Skin ulcer—Propylthiouracil—Graves' disease	0.00244	0.0411	CcSEcCtD
Thalidomide—NFKB1—eye—Graves' disease	0.00239	0.0946	CbGeAlD
Thalidomide—NFKB1—connective tissue—Graves' disease	0.00231	0.0911	CbGeAlD
Thalidomide—Aplastic anaemia—Methimazole—Graves' disease	0.0021	0.0353	CcSEcCtD
Thalidomide—Lymphadenopathy—Methimazole—Graves' disease	0.0019	0.032	CcSEcCtD
Thalidomide—FGFR2—eye—Graves' disease	0.0018	0.071	CbGeAlD
Thalidomide—Aplastic anaemia—Propylthiouracil—Graves' disease	0.00178	0.03	CcSEcCtD
Thalidomide—NFKB1—pituitary gland—Graves' disease	0.00178	0.0702	CbGeAlD
Thalidomide—NFKB1—adipose tissue—Graves' disease	0.00177	0.0699	CbGeAlD
Thalidomide—FGFR2—connective tissue—Graves' disease	0.00173	0.0684	CbGeAlD
Thalidomide—Lymphadenopathy—Propylthiouracil—Graves' disease	0.00161	0.0272	CcSEcCtD
Thalidomide—NFKB1—thyroid gland—Graves' disease	0.00153	0.0605	CbGeAlD
Thalidomide—Renal failure acute—Propylthiouracil—Graves' disease	0.00149	0.0252	CcSEcCtD
Thalidomide—CRBN—pituitary gland—Graves' disease	0.00149	0.0588	CbGeAlD
Thalidomide—CRBN—adipose tissue—Graves' disease	0.00148	0.0586	CbGeAlD
Thalidomide—Dermatitis exfoliative—Propylthiouracil—Graves' disease	0.00146	0.0246	CcSEcCtD
Thalidomide—FGFR2—adipose tissue—Graves' disease	0.00133	0.0525	CbGeAlD
Thalidomide—CRBN—thyroid gland—Graves' disease	0.00128	0.0507	CbGeAlD
Thalidomide—Drowsiness—Methimazole—Graves' disease	0.00125	0.0211	CcSEcCtD
Thalidomide—Neuropathy peripheral—Methimazole—Graves' disease	0.00122	0.0206	CcSEcCtD
Thalidomide—Agranulocytosis—Methimazole—Graves' disease	0.00117	0.0196	CcSEcCtD
Thalidomide—FGFR2—thyroid gland—Graves' disease	0.00115	0.0454	CbGeAlD
Thalidomide—Hepatitis—Methimazole—Graves' disease	0.00112	0.0189	CcSEcCtD
Thalidomide—Drowsiness—Propylthiouracil—Graves' disease	0.00106	0.0179	CcSEcCtD
Thalidomide—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00104	0.0175	CcSEcCtD
Thalidomide—Agranulocytosis—Propylthiouracil—Graves' disease	0.000991	0.0167	CcSEcCtD
Thalidomide—Alopecia—Methimazole—Graves' disease	0.00099	0.0167	CcSEcCtD
Thalidomide—Hepatitis—Propylthiouracil—Graves' disease	0.000953	0.0161	CcSEcCtD
Thalidomide—Vertigo—Methimazole—Graves' disease	0.000877	0.0148	CcSEcCtD
Thalidomide—Leukopenia—Methimazole—Graves' disease	0.000873	0.0147	CcSEcCtD
Thalidomide—Alopecia—Propylthiouracil—Graves' disease	0.000842	0.0142	CcSEcCtD
Thalidomide—Myalgia—Methimazole—Graves' disease	0.000831	0.014	CcSEcCtD
Thalidomide—Arthralgia—Methimazole—Graves' disease	0.000831	0.014	CcSEcCtD
Thalidomide—Dysgeusia—Propylthiouracil—Graves' disease	0.000812	0.0137	CcSEcCtD
Thalidomide—Oedema—Methimazole—Graves' disease	0.000796	0.0134	CcSEcCtD
Thalidomide—Thrombocytopenia—Methimazole—Graves' disease	0.00078	0.0131	CcSEcCtD
Thalidomide—Vertigo—Propylthiouracil—Graves' disease	0.000745	0.0126	CcSEcCtD
Thalidomide—Leukopenia—Propylthiouracil—Graves' disease	0.000743	0.0125	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methimazole—Graves' disease	0.000726	0.0122	CcSEcCtD
Thalidomide—Paraesthesia—Methimazole—Graves' disease	0.000715	0.0121	CcSEcCtD
Thalidomide—Somnolence—Methimazole—Graves' disease	0.000708	0.0119	CcSEcCtD
Thalidomide—Arthralgia—Propylthiouracil—Graves' disease	0.000706	0.0119	CcSEcCtD
Thalidomide—Myalgia—Propylthiouracil—Graves' disease	0.000706	0.0119	CcSEcCtD
Thalidomide—Dyspepsia—Methimazole—Graves' disease	0.000701	0.0118	CcSEcCtD
Thalidomide—Oedema—Propylthiouracil—Graves' disease	0.000677	0.0114	CcSEcCtD
Thalidomide—Thrombocytopenia—Propylthiouracil—Graves' disease	0.000663	0.0112	CcSEcCtD
Thalidomide—Urticaria—Methimazole—Graves' disease	0.000633	0.0107	CcSEcCtD
Thalidomide—Body temperature increased—Methimazole—Graves' disease	0.00063	0.0106	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.000617	0.0104	CcSEcCtD
Thalidomide—Paraesthesia—Propylthiouracil—Graves' disease	0.000608	0.0103	CcSEcCtD
Thalidomide—Somnolence—Propylthiouracil—Graves' disease	0.000602	0.0102	CcSEcCtD
Thalidomide—Dyspepsia—Propylthiouracil—Graves' disease	0.000596	0.0101	CcSEcCtD
Thalidomide—Pruritus—Methimazole—Graves' disease	0.000563	0.0095	CcSEcCtD
Thalidomide—PTGS1—connective tissue—Graves' disease	0.000551	0.0218	CbGeAlD
Thalidomide—Urticaria—Propylthiouracil—Graves' disease	0.000538	0.00907	CcSEcCtD
Thalidomide—Body temperature increased—Propylthiouracil—Graves' disease	0.000535	0.00903	CcSEcCtD
Thalidomide—PTGS2—connective tissue—Graves' disease	0.000527	0.0208	CbGeAlD
Thalidomide—Vomiting—Methimazole—Graves' disease	0.000506	0.00854	CcSEcCtD
Thalidomide—Rash—Methimazole—Graves' disease	0.000502	0.00847	CcSEcCtD
Thalidomide—Dermatitis—Methimazole—Graves' disease	0.000502	0.00846	CcSEcCtD
Thalidomide—Headache—Methimazole—Graves' disease	0.000499	0.00841	CcSEcCtD
Thalidomide—CYP1A1—adipose tissue—Graves' disease	0.000481	0.019	CbGeAlD
Thalidomide—Pruritus—Propylthiouracil—Graves' disease	0.000479	0.00808	CcSEcCtD
Thalidomide—Nausea—Methimazole—Graves' disease	0.000473	0.00798	CcSEcCtD
Thalidomide—CYP3A5—adipose tissue—Graves' disease	0.00047	0.0186	CbGeAlD
Thalidomide—Vomiting—Propylthiouracil—Graves' disease	0.000431	0.00726	CcSEcCtD
Thalidomide—Rash—Propylthiouracil—Graves' disease	0.000427	0.0072	CcSEcCtD
Thalidomide—Dermatitis—Propylthiouracil—Graves' disease	0.000427	0.00719	CcSEcCtD
Thalidomide—PTGS1—pituitary gland—Graves' disease	0.000424	0.0168	CbGeAlD
Thalidomide—Headache—Propylthiouracil—Graves' disease	0.000424	0.00715	CcSEcCtD
Thalidomide—PTGS1—adipose tissue—Graves' disease	0.000423	0.0167	CbGeAlD
Thalidomide—CYP1A2—thyroid gland—Graves' disease	0.000422	0.0167	CbGeAlD
Thalidomide—CYP1A1—thyroid gland—Graves' disease	0.000416	0.0164	CbGeAlD
Thalidomide—PTGS2—pituitary gland—Graves' disease	0.000406	0.016	CbGeAlD
Thalidomide—PTGS2—adipose tissue—Graves' disease	0.000404	0.016	CbGeAlD
Thalidomide—Nausea—Propylthiouracil—Graves' disease	0.000402	0.00678	CcSEcCtD
Thalidomide—CYP2E1—thyroid gland—Graves' disease	0.00038	0.015	CbGeAlD
Thalidomide—PTGS1—thyroid gland—Graves' disease	0.000366	0.0144	CbGeAlD
Thalidomide—NFKB1—Vitamin B12 Metabolism—IFNG—Graves' disease	0.000278	0.00431	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—CD40—Graves' disease	0.000276	0.00428	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—FASLG—Graves' disease	0.000276	0.00428	CbGpPWpGaD
Thalidomide—TNF—Monoamine Transport—IL1B—Graves' disease	0.000274	0.00425	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IFNG—Graves' disease	0.000273	0.00424	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	0.000272	0.00422	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—CD40—Graves' disease	0.000269	0.00418	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—FAS—Graves' disease	0.000269	0.00417	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-DQB1—Graves' disease	0.000268	0.00416	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis Modulation and Signaling—FAS—Graves' disease	0.000266	0.00413	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—IFNG—Graves' disease	0.000265	0.00411	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—CD4—Graves' disease	0.000264	0.0041	CbGpPWpGaD
Thalidomide—NFKB1—amb2 Integrin signaling—TNF—Graves' disease	0.000261	0.00405	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	0.000261	0.00405	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	0.000258	0.004	CbGpPWpGaD
Thalidomide—NFKB1—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—Graves' disease	0.000254	0.00395	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—ICAM1—Graves' disease	0.000249	0.00387	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—IL1B—Graves' disease	0.000248	0.00384	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—CXCL10—Graves' disease	0.000247	0.00383	CbGpPWpGaD
Thalidomide—TNF—IL23-mediated signaling events—IL1B—Graves' disease	0.000244	0.00378	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—IFNG—Graves' disease	0.000244	0.00378	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-B—Graves' disease	0.000241	0.00374	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—CXCL10—Graves' disease	0.000241	0.00374	CbGpPWpGaD
Thalidomide—NFKB1—DNA Damage Response (only ATM dependent)—FASLG—Graves' disease	0.000239	0.00371	CbGpPWpGaD
Thalidomide—NFKB1—TCR signaling—CD4—Graves' disease	0.000239	0.0037	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000236	0.00366	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—FASLG—Graves' disease	0.000236	0.00365	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—CD4—Graves' disease	0.000235	0.00365	CbGpPWpGaD
Thalidomide—PTGS1—Overview of nanoparticle effects—TNF—Graves' disease	0.000235	0.00364	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—HLA-E—Graves' disease	0.000235	0.00364	CbGpPWpGaD
Thalidomide—NFKB1—IL-1 signaling pathway—IL1B—Graves' disease	0.000233	0.00362	CbGpPWpGaD
Thalidomide—NFKB1—IL23-mediated signaling events—TNF—Graves' disease	0.000232	0.0036	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL2RA—Graves' disease	0.000231	0.00358	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.00023	0.00356	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—FAS—Graves' disease	0.000227	0.00352	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—FAS—Graves' disease	0.000227	0.00352	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—ICAM1—Graves' disease	0.000226	0.00351	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL2RA—Graves' disease	0.000226	0.0035	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—IFNG—Graves' disease	0.000226	0.0035	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—FASLG—Graves' disease	0.000224	0.00348	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-A—Graves' disease	0.000223	0.00346	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-E—Graves' disease	0.000221	0.00343	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of Telomerase—IFNG—Graves' disease	0.00022	0.00342	CbGpPWpGaD
Thalidomide—NFKB1—IL12-mediated signaling events—IL1B—Graves' disease	0.000217	0.00337	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—FAS—Graves' disease	0.000216	0.00336	CbGpPWpGaD
Thalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000215	0.00333	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—CXCL10—Graves' disease	0.000214	0.00333	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—IFNG—Graves' disease	0.000211	0.00328	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—CD40—Graves' disease	0.00021	0.00326	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—Graves' disease	0.00021	0.00326	CbGpPWpGaD
Thalidomide—NFKB1—TWEAK Signaling Pathway—TNF—Graves' disease	0.00021	0.00326	CbGpPWpGaD
Thalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—Graves' disease	0.000205	0.00319	CbGpPWpGaD
Thalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000205	0.00318	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—HLA-DRB1—Graves' disease	0.000204	0.00317	CbGpPWpGaD
Thalidomide—TNF—TGF-beta Receptor Signaling—IFNG—Graves' disease	0.000202	0.00313	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—IL1B—Graves' disease	0.000201	0.00312	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—Graves' disease	0.000201	0.00312	CbGpPWpGaD
Thalidomide—NFKB1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	0.000195	0.00303	CbGpPWpGaD
Thalidomide—NFKB1—TNF receptor signaling pathway —TNF—Graves' disease	0.000195	0.00303	CbGpPWpGaD
Thalidomide—NFKB1—Glucocorticoid receptor regulatory network—IFNG—Graves' disease	0.00019	0.00294	CbGpPWpGaD
Thalidomide—TNF—Vitamin B12 Metabolism—IL1B—Graves' disease	0.000189	0.00293	CbGpPWpGaD
Thalidomide—NFKB1—Ceramide signaling pathway—TNF—Graves' disease	0.000189	0.00293	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL10—Graves' disease	0.000188	0.00292	CbGpPWpGaD
Thalidomide—PTGS2—Overview of nanoparticle effects—TNF—Graves' disease	0.000186	0.00289	CbGpPWpGaD
Thalidomide—NFKB1—Angiopoietin receptor Tie2-mediated signaling—TNF—Graves' disease	0.000183	0.00283	CbGpPWpGaD
Thalidomide—NFKB1—Leptin signaling pathway—IL1B—Graves' disease	0.000182	0.00282	CbGpPWpGaD
Thalidomide—NFKB1—Vitamin B12 Metabolism—TNF—Graves' disease	0.00018	0.00279	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—ICAM1—Graves' disease	0.00018	0.00279	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—IFNG—Graves' disease	0.000179	0.00278	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—Graves' disease	0.000174	0.0027	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—IFNG—Graves' disease	0.000172	0.00267	CbGpPWpGaD
Thalidomide—TNF—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	0.000172	0.00267	CbGpPWpGaD
Thalidomide—NFKB1—TGF-beta Receptor Signaling—TNF—Graves' disease	0.000172	0.00266	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—CD4—Graves' disease	0.00017	0.00264	CbGpPWpGaD
Thalidomide—NFKB1—Cardiac Hypertrophic Response—TNF—Graves' disease	0.000169	0.00262	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—FASLG—Graves' disease	0.000169	0.00262	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—FAS—Graves' disease	0.000163	0.00253	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-E—Graves' disease	0.000161	0.0025	CbGpPWpGaD
Thalidomide—FGFR2—Cardiac Hypertrophic Response—TNF—Graves' disease	0.00016	0.00249	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—IL1B—Graves' disease	0.00016	0.00248	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HLA-B—Graves' disease	0.000157	0.00244	CbGpPWpGaD
Thalidomide—NFKB1—TCR Signaling Pathway—IL1B—Graves' disease	0.000157	0.00244	CbGpPWpGaD
Thalidomide—TNF—Folate Metabolism—IL1B—Graves' disease	0.000153	0.00238	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000153	0.00237	CbGpPWpGaD
Thalidomide—TNF—Adipogenesis—FAS—Graves' disease	0.000152	0.00237	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IFNG—Graves' disease	0.000149	0.00231	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000147	0.00228	CbGpPWpGaD
Thalidomide—NFKB1—Folate Metabolism—TNF—Graves' disease	0.000146	0.00227	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000142	0.00221	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—ICAM1—Graves' disease	0.000142	0.0022	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—ICAM1—Graves' disease	0.00014	0.00217	CbGpPWpGaD
Thalidomide—NFKB1—Signaling events mediated by HDAC Class I—TNF—Graves' disease	0.000139	0.00216	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—FASLG—Graves' disease	0.000137	0.00213	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IFNG—Graves' disease	0.000137	0.00212	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL1B—Graves' disease	0.000136	0.00211	CbGpPWpGaD
Thalidomide—TNF—Allograft Rejection—IL1B—Graves' disease	0.000133	0.00206	CbGpPWpGaD
Thalidomide—TNF—Alzheimers Disease—IL1B—Graves' disease	0.000133	0.00206	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—Graves' disease	0.000133	0.00206	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CXCL10—Graves' disease	0.000133	0.00206	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—FAS—Graves' disease	0.000132	0.00206	CbGpPWpGaD
Thalidomide—NFKB1—Transcriptional regulation of white adipocyte differentiation—TNF—Graves' disease	0.000129	0.002	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—FASLG—Graves' disease	0.000129	0.002	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	0.000128	0.00199	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	0.000126	0.00196	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—FAS—Graves' disease	0.000124	0.00193	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IL1B—Graves' disease	0.000122	0.00189	CbGpPWpGaD
Thalidomide—NFKB1—Apoptosis—TNF—Graves' disease	0.000121	0.00187	CbGpPWpGaD
Thalidomide—NFKB1—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000121	0.00187	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—GC—Graves' disease	0.000117	0.00181	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	0.000116	0.0018	CbGpPWpGaD
Thalidomide—NFKB1—Selenium Micronutrient Network—TNF—Graves' disease	0.000116	0.0018	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IFIH1—Graves' disease	0.000115	0.00178	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-B—Graves' disease	0.000115	0.00178	CbGpPWpGaD
Thalidomide—FGFR2—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	0.000114	0.00177	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	0.000112	0.00174	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	0.000112	0.00174	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—TNF—Graves' disease	0.000112	0.00174	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—ICAM1—Graves' disease	0.000111	0.00172	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	0.000111	0.00172	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IFIH1—Graves' disease	0.000109	0.00169	CbGpPWpGaD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—Graves' disease	0.000108	0.00168	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IFNG—Graves' disease	0.000108	0.00168	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL2RA—Graves' disease	0.000108	0.00167	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-A—Graves' disease	0.000107	0.00165	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IFNG—Graves' disease	0.000106	0.00165	CbGpPWpGaD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—TNF—Graves' disease	0.000103	0.0016	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL1B—Graves' disease	0.000102	0.00158	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL1B—Graves' disease	0.000101	0.00157	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	9.73e-05	0.00151	CbGpPWpGaD
Thalidomide—TNF—Spinal Cord Injury—IL1B—Graves' disease	9.64e-05	0.0015	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—IL1B—Graves' disease	9.54e-05	0.00148	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL1B—Graves' disease	9.5e-05	0.00147	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—ICAM1—Graves' disease	9.34e-05	0.00145	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—GC—Graves' disease	9.28e-05	0.00144	CbGpPWpGaD
Thalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	9.19e-05	0.00143	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HLA-E—Graves' disease	9.05e-05	0.0014	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—ICAM1—Graves' disease	8.79e-05	0.00136	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-E—Graves' disease	8.69e-05	0.00135	CbGpPWpGaD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—Graves' disease	8.6e-05	0.00133	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HLA-E—Graves' disease	8.58e-05	0.00133	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD40—Graves' disease	8.49e-05	0.00132	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—CD4—Graves' disease	8.47e-05	0.00131	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—Graves' disease	8.46e-05	0.00131	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IFNG—Graves' disease	8.45e-05	0.00131	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CTLA4—Graves' disease	8.37e-05	0.0013	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-E—Graves' disease	8.24e-05	0.00128	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GC—Graves' disease	8.24e-05	0.00128	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	8.16e-05	0.00127	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	8.16e-05	0.00127	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD40—Graves' disease	8.06e-05	0.00125	CbGpPWpGaD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—Graves' disease	8.05e-05	0.00125	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	8.04e-05	0.00125	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CTLA4—Graves' disease	7.94e-05	0.00123	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL1B—Graves' disease	7.71e-05	0.0012	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL1B—Graves' disease	7.54e-05	0.00117	CbGpPWpGaD
Thalidomide—FGFR2—Disease—B3GNT2—Graves' disease	7.53e-05	0.00117	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—Graves' disease	7.34e-05	0.00114	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—IL1B—Graves' disease	7.27e-05	0.00113	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	7.19e-05	0.00112	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	7.17e-05	0.00111	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IFNG—Graves' disease	7.11e-05	0.0011	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	6.93e-05	0.00108	CbGpPWpGaD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—Graves' disease	6.92e-05	0.00107	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—Graves' disease	6.89e-05	0.00107	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DQB1—Graves' disease	6.89e-05	0.00107	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.74e-05	0.00105	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFIH1—Graves' disease	6.7e-05	0.00104	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IFNG—Graves' disease	6.68e-05	0.00104	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DQB1—Graves' disease	6.54e-05	0.00101	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HLA-B—Graves' disease	6.45e-05	0.001	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD8A—Graves' disease	6.44e-05	0.000998	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFIH1—Graves' disease	6.35e-05	0.000986	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1B—Graves' disease	6.34e-05	0.000983	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	6.25e-05	0.000969	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-B—Graves' disease	6.19e-05	0.00096	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GC—Graves' disease	6.15e-05	0.000953	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HLA-B—Graves' disease	6.12e-05	0.000949	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD8A—Graves' disease	6.11e-05	0.000947	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL1B—Graves' disease	5.96e-05	0.000925	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-B—Graves' disease	5.87e-05	0.000911	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-A—Graves' disease	5.74e-05	0.00089	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—Graves' disease	5.47e-05	0.000849	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-A—Graves' disease	5.44e-05	0.000844	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-E—Graves' disease	5.27e-05	0.000817	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	5.25e-05	0.000815	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HLA-DRB1—Graves' disease	5.24e-05	0.000813	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GC—Graves' disease	5.21e-05	0.000808	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	5.2e-05	0.000807	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	5.2e-05	0.000807	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD40—Graves' disease	5.15e-05	0.000799	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTLA4—Graves' disease	5.08e-05	0.000787	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—ICAM1—Graves' disease	5.03e-05	0.00078	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-E—Graves' disease	5e-05	0.000776	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HLA-DRB1—Graves' disease	4.97e-05	0.000771	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD40—Graves' disease	4.89e-05	0.000758	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTLA4—Graves' disease	4.82e-05	0.000747	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—ICAM1—Graves' disease	4.77e-05	0.00074	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSHR—Graves' disease	4.61e-05	0.000715	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSHR—Graves' disease	4.37e-05	0.000678	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—Graves' disease	4.33e-05	0.000671	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DQB1—Graves' disease	4.18e-05	0.000648	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GC—Graves' disease	4.13e-05	0.000641	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DQB1—Graves' disease	3.97e-05	0.000615	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—B3GNT2—Graves' disease	3.95e-05	0.000612	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—Graves' disease	3.9e-05	0.000606	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GC—Graves' disease	3.89e-05	0.000604	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GC—Graves' disease	3.88e-05	0.000602	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—Graves' disease	3.85e-05	0.000597	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-B—Graves' disease	3.75e-05	0.000582	CbGpPWpGaD
Thalidomide—PTGS2—Disease—B3GNT2—Graves' disease	3.74e-05	0.00058	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—Graves' disease	3.7e-05	0.000575	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—Graves' disease	3.7e-05	0.000573	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GC—Graves' disease	3.67e-05	0.000569	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—Graves' disease	3.65e-05	0.000567	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-B—Graves' disease	3.56e-05	0.000553	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2RA—Graves' disease	3.52e-05	0.000546	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—Graves' disease	3.51e-05	0.000544	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-A—Graves' disease	3.48e-05	0.00054	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2RA—Graves' disease	3.34e-05	0.000518	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-A—Graves' disease	3.3e-05	0.000512	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—Graves' disease	3.18e-05	0.000493	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—B3GNT2—Graves' disease	3.13e-05	0.000486	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ICAM1—Graves' disease	3.05e-05	0.000473	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HLA-A—Graves' disease	3.05e-05	0.000473	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—Graves' disease	3.02e-05	0.000468	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GC—Graves' disease	3e-05	0.000466	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL10—Graves' disease	2.98e-05	0.000462	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—B3GNT2—Graves' disease	2.95e-05	0.000457	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	2.94e-05	0.000457	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—B3GNT2—Graves' disease	2.94e-05	0.000456	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—Graves' disease	2.92e-05	0.000453	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ICAM1—Graves' disease	2.89e-05	0.000449	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL10—Graves' disease	2.82e-05	0.000438	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—B3GNT2—Graves' disease	2.78e-05	0.000431	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GC—Graves' disease	2.74e-05	0.000425	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GC—Graves' disease	2.34e-05	0.000363	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—Graves' disease	2.32e-05	0.00036	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—B3GNT2—Graves' disease	2.27e-05	0.000353	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2RA—Graves' disease	2.27e-05	0.000353	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—Graves' disease	2.24e-05	0.000348	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—Graves' disease	2.2e-05	0.000342	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2RA—Graves' disease	2.16e-05	0.000335	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—Graves' disease	2.13e-05	0.00033	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—B3GNT2—Graves' disease	2.07e-05	0.000322	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—Graves' disease	2.07e-05	0.000321	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—Graves' disease	1.96e-05	0.000305	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—Graves' disease	1.96e-05	0.000305	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—B3GNT2—Graves' disease	1.77e-05	0.000275	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HLA-A—Graves' disease	1.51e-05	0.000235	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—Graves' disease	9.75e-06	0.000151	CbGpPWpGaD
